Drugs.com - New Drug Approvals

Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 18, 2025-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody...

Jun 23, 2025 - 00:20
 0
Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 18, 2025-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody...
Read More

Tags:

Previous Article

Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profil...

Next Article

Toyota & Airbus Push Hydrogen Fuel Cell Dreams

Related Posts

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRE...

Jun 13, 2025  0

FDA Approves Conexxence (denosumab-bnht), a Biosimilar ...

May 12, 2025  0

FDA Approves Enflonsia (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants

FDA Approves Enflonsia (clesrovimab-cfor) for Preventio...

Jun 9, 2025  0